Your browser doesn't support javascript.
loading
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Pérez-García, José Manuel; Gebhart, Geraldine; Ruiz Borrego, Manuel; Stradella, Agostina; Bermejo, Begoña; Schmid, Peter; Marmé, Frederik; Escrivá-de-Romani, Santiago; Calvo, Lourdes; Ribelles, Nuria; Martinez, Noelia; Albacar, Cinta; Prat, Aleix; Dalenc, Florence; Kerrou, Khaldoun; Colleoni, Marco; Afonso, Noemia; Di Cosimo, Serena; Sampayo-Cordero, Miguel; Malfettone, Andrea; Cortés, Javier; Llombart-Cussac, Antonio.
Afiliación
  • Pérez-García JM; International Breast Cancer Center, Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research, Barcelona, Spain; Medica Scientia Innovation Research, Ridgewood, NJ, USA.
  • Gebhart G; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
  • Ruiz Borrego M; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Stradella A; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Bermejo B; Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Schmid P; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, UK; Barts Hospital NHS Trust, London, UK.
  • Marmé F; University Hospital Heidelberg, Medical Faculty Mannheim Heidelberg University, Heidelberg, Germany.
  • Escrivá-de-Romani S; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Calvo L; Hospital Universitario A Coruña, UGC Oncología Intercentros, A Coruña, Spain.
  • Ribelles N; Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain; Medical Oncology Service, Instituto de Investigaciones Biomédicas de Málaga, Malaga, Spain.
  • Martinez N; Medical Oncology, University Hospital Ramón y Cajal, Madrid, Spain.
  • Albacar C; Department of Medical Oncology, Hospital Universitari Sant Joan de Reus, Reus, Spain.
  • Prat A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies Group, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain.
  • Dalenc F; Institut Claudius Regaud, IUCT-Oncopole, Toulouse Cancer Research Centre, INSERM, Toulouse, France.
  • Kerrou K; APHP, Tenon Hospital IUC-UPMC, Nuclear Medicine and PET Center Department, Sorbonne University, Paris, France.
  • Colleoni M; IRCCS European Institute of Oncology, Division of Medical Senology, Milan, Italy.
  • Afonso N; Centro Hospitalar Universitário do Porto, Porto, Portugal.
  • Di Cosimo S; Medica Scientia Innovation Research, Barcelona, Spain; Medica Scientia Innovation Research, Ridgewood, NJ, USA; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Sampayo-Cordero M; Medica Scientia Innovation Research, Barcelona, Spain; Medica Scientia Innovation Research, Ridgewood, NJ, USA.
  • Malfettone A; Medica Scientia Innovation Research, Barcelona, Spain; Medica Scientia Innovation Research, Ridgewood, NJ, USA.
  • Cortés J; International Breast Cancer Center, Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research, Barcelona, Spain; Medica Scientia Innovation Research, Ridgewood, NJ, USA; Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: jacortes@vhio.net.
  • Llombart-Cussac A; Medica Scientia Innovation Research, Barcelona, Spain; Medica Scientia Innovation Research, Ridgewood, NJ, USA; Hospital Arnau de Vilanova, Universidad Catolica, Valencia, Spain.
Lancet Oncol ; 22(6): 858-871, 2021 06.
Article en En | MEDLINE | ID: mdl-34019819
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatino / Docetaxel Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatino / Docetaxel Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos